期刊文献+

预测冠心病患者冠状动脉介入术后长期效果的预测因素 被引量:7

Predictive factors for the long-term outcomes in patients undergoing percutaneous coronary intervention
原文传递
导出
摘要 目的:分析预测冠心病患者冠状动脉介入治疗术(PCI)后长期临床效果的预测因素。方法:收集592例冠心病患者PCI后的临床资料并进行随访,随访主要不良心血管事件(MACE)发生情况并经多元logistic回归的方法分析这些事件的相关因素。结果:平均随访时间18.96(3~57)个月。MACE的发生率为7.6%,全因性死亡率为2.4%,非致死性心肌梗死发生率为1.5%。MACE发生的预测因素有PCI方式、近段病变、参考血管的直径及氯吡格雷的应用时间,年龄、有心肌梗死史及氯吡格雷应用时间可预测全因性死亡,术后未戒烟及完全停止抗血小板治疗增加非致死性心肌梗死的危险。结论:高龄、单纯经皮冠状动脉球囊成形术或置入金属裸支架、小血管病变、近段病变和对抗血小板治疗及戒烟的依从性差是预测PCI后不良预后的因素。 Objective:To explore the predictive factors for long-term outcomes in patients undergoing percutaneous coronary intervention (PCI) in real world. Method:The clinical data was collected in 592 patients undergoing PCI in our department,major adverse cardiac events (MACE was defined as all-cause death,nonfatal myocardial infarction and coronary revascularization) was carefully recorded at follow-up,their relationship was analyzed by multi-variables stepwise logistic regression. Result:The average follow-up was 18.96 months(3-57 months). At follow-up,the cumulative incidence of MACE was 7.6%,the all-cause morality was 2.4%,the prevalence of non-fatal myocardial infarct was 1.5%. The predictive factors for MACE were type of PCI,proximal lesion,referral coronary diameter,and the duration of prescribed clopidogrel. Age,previous myocardial infarction and premature withdrawal of clopidogrel were positively related to the all-cause death,current smoking and the discontinuation of antiplatelet therapy were associated with the increased risk of nonfatal myocardial infarction. Conclusion:The predictors for MACE include age,type of PCI,the smaller coronary artery,proximal lesion,nonadherence to antiplatelet therapy and cessation of smoking.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2009年第9期677-680,共4页 Journal of Clinical Cardiology
关键词 冠心病 血管成形术 经腔 经皮冠状动脉 预测因素 长期预后 angioplasty transluminal percutaneous coronary predictive factors long-term outcomes
  • 相关文献

参考文献1

  • 1Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿(译),David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志(中文版),2007,26(3):131-139. 被引量:59

二级参考文献28

  • 1Moses JW, Leon MB, Poprna JJ, et al. Sirolimus-eluting s-tents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003,349:1315-1323.
  • 2Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-Ⅳ trial. Circulation. 2004;109:1942 - 1947.
  • 3Moses JW. CYPHER trials. Presented at: American College of Cardiology Annual Scientific Session 2006 Rapid News Summaries; March 11-14, 2006; Atlanta, Ga. http://www.cardiosource.com /rapid newssu mmaries/index.asp?EID=22 &DoW=Mon&SumID=165. Accessed July 1, 2006.
  • 4Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report fiom the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113:e85-e151.
  • 5Leon MB, Bairn DS, Popma J J, et al; Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenUng. N Engl J Med. 1998;339: 1665-1671.
  • 6Cutlip DE, Balm DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001, 103:1967-1971.
  • 7Berger PB, Mahaffey KW, Meier S J, et al. Safety and efficacy of only 2 weeks of ticlopicline therapy in patients at increased dsk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J. 2002;143:841-846.
  • 8Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
  • 9Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug- eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803-2809.
  • 10Regar E, Lemos PA, Saia F, et al. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. Am J Cardiol. 2004;93:1271- 1275.

共引文献58

同被引文献46

引证文献7

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部